High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The Efa VIP study (Efavirenz in very immunosuppressed patients)

  1. Arribas, J.R.
  2. Pulido, F.
  3. Miró, J.M.
  4. Costa, M.A.
  5. González, J.
  6. Rubio, R.
  7. Peña, J.M.
  8. Torralba, M.
  9. Lonca, M.
  10. Lorenzo, A.
  11. Del Palacio, A.
  12. Vázquez, J.J.
  13. Gatell, J.M.
Journal:
AIDS

ISSN: 0269-9370

Year of publication: 2002

Volume: 16

Issue: 11

Pages: 1554-1556

Type: Article

DOI: 10.1097/00002030-200207260-00014 GOOGLE SCHOLAR

Sustainable development goals